Perspective Therapeutics Inc. (CATX) - Total Liabilities
Based on the latest financial reports, Perspective Therapeutics Inc. (CATX) has total liabilities worth $63.33 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore CATX net asset momentum to track the company's year-over-year net asset growth rate.
Perspective Therapeutics Inc. - Total Liabilities Trend (1994–2025)
This chart illustrates how Perspective Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Perspective Therapeutics Inc. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Perspective Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Perspective Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BlackRock Municipal Income Closed Fund
NYSE:BFK
|
USA | $337.82 Million |
|
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
NYSE:HQ
|
USA | $27.18 Million |
|
PRIMA MARINE PCL-NVDR
BK:PRM-R
|
Thailand | ฿10.45 Billion |
|
Tongqinglou Dining Co Ltd
SHG:605108
|
China | CN¥3.32 Billion |
|
Vishnu Chemicals Limited
NSE:VISHNU
|
India | Rs10.13 Billion |
|
Shanghai Morn Electric Equipment Co Ltd
SHE:002451
|
China | CN¥1.06 Billion |
|
Dalian Thermal Power Co Ltd
SHG:600719
|
China | CN¥1.85 Billion |
|
Long Chen Paper Co Ltd
TW:1909
|
Taiwan | NT$48.43 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Perspective Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CATX market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Perspective Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Perspective Therapeutics Inc. (1994–2025)
The table below shows the annual total liabilities of Perspective Therapeutics Inc. from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $59.94 Million | +18.85% |
| 2024-12-31 | $50.43 Million | +122.05% |
| 2023-12-31 | $22.71 Million | +558.51% |
| 2023-06-30 | $3.45 Million | 0.00% |
| 2022-12-31 | $3.45 Million | +9.08% |
| 2022-06-30 | $3.16 Million | 0.00% |
| 2021-12-31 | $3.16 Million | +5.05% |
| 2021-06-30 | $3.01 Million | +9.85% |
| 2020-12-31 | $2.74 Million | -7.93% |
| 2020-06-30 | $2.98 Million | 0.00% |
| 2019-12-31 | $2.98 Million | +70.84% |
| 2019-06-30 | $1.74 Million | 0.00% |
| 2018-12-31 | $1.74 Million | -28.16% |
| 2018-06-30 | $2.42 Million | +45.47% |
| 2017-12-31 | $1.67 Million | 0.00% |
| 2017-06-30 | $1.67 Million | -1.99% |
| 2016-12-31 | $1.70 Million | 0.00% |
| 2016-06-30 | $1.70 Million | -23.42% |
| 2015-12-31 | $2.22 Million | 0.00% |
| 2015-06-30 | $2.22 Million | -14.36% |
| 2014-12-31 | $2.59 Million | 0.00% |
| 2014-06-30 | $2.59 Million | +53.54% |
| 2013-12-31 | $1.69 Million | 0.00% |
| 2013-06-30 | $1.69 Million | +0.11% |
| 2012-12-31 | $1.69 Million | 0.00% |
| 2012-06-30 | $1.69 Million | +17.47% |
| 2011-12-31 | $1.44 Million | 0.00% |
| 2011-06-30 | $1.44 Million | -17.78% |
| 2010-12-31 | $1.75 Million | 0.00% |
| 2010-06-30 | $1.75 Million | -1.78% |
| 2009-12-31 | $1.78 Million | 0.00% |
| 2009-06-30 | $1.78 Million | -12.69% |
| 2008-12-31 | $2.04 Million | 0.00% |
| 2008-06-30 | $2.04 Million | -39.37% |
| 2007-12-31 | $3.36 Million | 0.00% |
| 2007-06-30 | $3.36 Million | +21.29% |
| 2006-12-31 | $2.77 Million | 0.00% |
| 2006-06-30 | $2.77 Million | -87.03% |
| 2005-06-30 | $21.36 Million | 0.00% |
| 2004-12-31 | $21.36 Million | +3678.79% |
| 2004-06-30 | $565.13K | -47.86% |
| 2003-12-31 | $1.08 Million | 0.00% |
| 2003-06-30 | $1.08 Million | +4.89% |
| 2002-12-31 | $1.03 Million | 0.00% |
| 2002-06-30 | $1.03 Million | -19.47% |
| 2001-12-31 | $1.28 Million | +4.75% |
| 2000-12-31 | $1.23 Million | -4.54% |
| 2000-06-30 | $1.28 Million | -61.23% |
| 1999-12-31 | $3.31 Million | +170.16% |
| 1999-06-30 | $1.23 Million | -63.79% |
| 1998-12-31 | $3.38 Million | +2.23% |
| 1998-06-30 | $3.31 Million | -9.17% |
| 1997-12-31 | $3.64 Million | +7.69% |
| 1997-06-30 | $3.38 Million | +29.78% |
| 1996-12-31 | $2.61 Million | -28.45% |
| 1996-06-30 | $3.64 Million | +41.17% |
| 1995-12-31 | $2.58 Million | -1.00% |
| 1995-06-30 | $2.61 Million | +1.01% |
| 1994-12-31 | $2.58 Million | 0.00% |
| 1994-06-30 | $2.58 Million | -- |
About Perspective Therapeutics Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors t… Read more